Arcutis Biotherapeutics Inc. (ARQT): Price and Financial Metrics


Arcutis Biotherapeutics Inc. (ARQT): $16.56

0.46 (+2.86%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ARQT to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

ARQT Stock Price Chart Interactive Chart >

Price chart for ARQT

ARQT Price/Volume Stats

Current price $16.56 52-week high $27.40
Prev. close $16.10 52-week low $12.81
Day low $15.83 Volume 584,168
Day high $16.65 Avg. volume 842,739
50-day MA $16.08 Dividend yield N/A
200-day MA $19.74 Market Cap 1.01B

Arcutis Biotherapeutics Inc. (ARQT) Company Bio


Arcutis Biotherapeutics, Inc. engages in the development and commercialization of treatments for dermatological diseases. Its piepline consists of topical treatments for plaque psoriasis, atopic dermatitis, eczema, vitiligo, alopecia areata, and seborrheic dermatitis. The company was founded by Bhaskar Chaudhuri and David W. Osborne on June 1, 2016 and is headquartered in Westlake Village, CA.


ARQT Latest News Stream


Event/Time News Detail
Loading, please wait...

ARQT Latest Social Stream


Loading social stream, please wait...

View Full ARQT Social Stream

Latest ARQT News From Around the Web

Below are the latest news stories about ARCUTIS BIOTHERAPEUTICS INC that investors may wish to consider to help them evaluate ARQT as an investment opportunity.

Arcutis' Flagship Psoriasis Treatment Shows Sustained Efficacy, Clearance For Median Of 10 Months

Arcutis Biotherapeutics Inc (NASDAQ: ARQT) announced new safety and efficacy durability data from its open-label Phase 2 long-term safety study of roflumilast cream (0.3%) in adults with chronic plaque psoriasis. Roflumilast cream 0.3% (Zoryve) is a once-daily steroid-free topical phosphodiesterase-4 inhibitor approved by the FDA in July 2022. The study showed that during the trial, 57.1% (n=185) of roflumilast cream-treated patients achieved an Investigator Global Assessment (IGA) score of clea

Yahoo | January 17, 2023

Arcutis Presents New Phase 2 Long-Term Data Showing Sustained Efficacy and Clearance for a Median of 10 Months with Roflumilast Cream in Adults with Chronic Plaque Psoriasis

During the open label trial, 57.1% of roflumilast-treated participants achieved Investigator Global Assessment (IGA) of clear or almost clear at any time in study; the median duration of clear or almost clear was 10 months (40.1 weeks)Efficacy was consistent over time across all endpoints, and no lessening of response (no tachyphylaxis) from roflumilast cream was observedLong-term IGA success and Intertriginous-Investigator Global Assessment (I-IGA) success results are consistent with results fr

Yahoo | January 14, 2023

The Arcutis Biotherapeutics Inc. (ARQT) had a good session last reading, didn’t it?

A share of Arcutis Biotherapeutics Inc. (NASDAQ:ARQT) closed at $13.79 per share on Tuesday, down from $14.48 day before. While Arcutis Biotherapeutics Inc. has underperformed by -4.77%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ARQT fell by -26.10%, with highs and lows ranging from $27.40 […]

US Post News | January 11, 2023

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WESTLAKE VILLAGE, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 17,050 restricted stock units of Arcutis’ common stock as well as options to purchase an aggregate of 33,550 shares of Arcutis’ common stock to five newly hired employees. These awards were approved by the Compensation Committee o

Yahoo | January 5, 2023

Investing in Arcutis Biotherapeutics Inc. (ARQT) might be a great opportunity, but the stock is a bit overvalued

Arcutis Biotherapeutics Inc. (NASDAQ:ARQT) marked $14.59 per share on Thursday, up from a previous closing price of $14.06. While Arcutis Biotherapeutics Inc. has overperformed by 3.77%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ARQT fell by -28.79%, with highs and lows ranging from $27.40 to […]

US Post News | December 30, 2022

Read More 'ARQT' Stories Here

ARQT Price Returns

1-mo 17.78%
3-mo -5.37%
6-mo -31.74%
1-year 15.16%
3-year N/A
5-year N/A
YTD 11.89%
2022 -28.64%
2021 -26.27%
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6781 seconds.